Algernon Pharmaceuticals Inc
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of s… Read more
Algernon Pharmaceuticals Inc (AGNPF) - Total Liabilities
Latest total liabilities as of November 2025: $2.44 Million USD
Based on the latest financial reports, Algernon Pharmaceuticals Inc (AGNPF) has total liabilities worth $2.44 Million USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Algernon Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Algernon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Algernon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Algernon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WestKam Gold Corp
PINK:WKGFF
|
USA | $902.31K |
|
Etga Group Ltd
TA:ETGA
|
Israel | ILA547.23 Million |
|
Identitii Ltd
AU:ID8
|
Australia | AU$1.96 Million |
|
Prima Alloy Steel Universal
JK:PRAS
|
Indonesia | Rp1.19 Trillion |
|
Webco Industries Inc
PINK:WEBC
|
USA | $195.06 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Algernon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Algernon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Algernon Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of Algernon Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $2.18 Million | +22.91% |
| 2024-08-31 | $1.78 Million | -34.72% |
| 2023-08-31 | $2.72 Million | +8.09% |
| 2022-08-31 | $2.52 Million | +146.12% |
| 2021-08-31 | $1.02 Million | +68.41% |
| 2020-08-31 | $607.05K | +66.10% |
| 2019-08-31 | $365.46K | +540.78% |
| 2018-08-31 | $57.03K | +19.44% |
| 2017-08-31 | $47.75K | -68.25% |
| 2016-08-31 | $150.38K | -- |